Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) EPS (Basic) (2016 - 2025)

Perspective Therapeutics' EPS (Basic) history spans 16 years, with the latest figure at $0.01 for Q2 2025.

  • For Q2 2025, EPS (Basic) rose 104.33% year-over-year to $0.01; the TTM value through Sep 2025 reached $0.01, up 100.55%, while the annual FY2024 figure was -$1.23, 12.14% up from the prior year.
  • EPS (Basic) for Q2 2025 was $0.01 at Perspective Therapeutics, up from -$0.61 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.01 in Q2 2025 and bottomed at -$0.66 in Q4 2023.
  • The 5-year median for EPS (Basic) is -$0.03 (2022), against an average of -$0.16.
  • The largest annual shift saw EPS (Basic) tumbled 3900.0% in 2023 before it surged 104.33% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.01 in 2021, then plummeted by 300.0% to -$0.04 in 2022, then tumbled by 1550.0% to -$0.66 in 2023, then grew by 7.58% to -$0.61 in 2024, then soared by 101.14% to $0.01 in 2025.
  • Per Business Quant, the three most recent readings for CATX's EPS (Basic) are $0.01 (Q2 2025), -$0.61 (Q4 2024), and -$0.21 (Q3 2024).